<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30056767</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Expert review of vaccines</Title><ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation></Journal><ArticleTitle>Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.</ArticleTitle><Pagination><StartPage>739</StartPage><EndPage>751</EndPage><MedlinePgn>739-751</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14760584.2018.1506333</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Ending all cases of poliomyelitis requires successful cessation of all oral poliovirus vaccine (OPV), but the Global Polio Eradication Initiative (GPEI) partners should consider the possibility of an OPV restart.</AbstractText><AbstractText Label="AREAS COVERED">We review the risks of continued live poliovirus transmission after OPV cessation and characterize events that led to OPV restart in a global model that focused on identifying optimal strategies for OPV cessation and the polio endgame. Numerous different types of events that occurred since the globally coordinated cessation of serotype 2-containing OPV in 2016 highlight the possibility of continued outbreaks after homotypic OPV cessation. Modeling suggests a high risk of uncontrolled outbreaks once more than around 5,000 homotypic polio cases occur after cessation of an OPV serotype, at which point restarting OPV would become necessary to protect most populations. Current efforts to sunset the GPEI and transition its responsibilities to national governments poses risks that may limit the ability to implement management strategies needed to minimize the probability of an OPV restart.</AbstractText><AbstractText Label="EXPERT COMMENTARY">OPV restart remains a real possibility, but risk management choices made by the GPEI partners and national governments can reduce the risks of this low-probability but high-consequence event.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duintjer Tebbens</LastName><ForeName>Radboud J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>a Kid Risk, Inc ., Columbus , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>a Kid Risk, Inc ., Columbus , USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Vaccines</MedlineTA><NlmUniqueID>101155475</NlmUniqueID><ISSNLinking>1476-0584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012308" MajorTopicYN="N">Risk Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">disease outbreaks</Keyword><Keyword MajorTopicYN="N">dynamic modeling</Keyword><Keyword MajorTopicYN="N">eradication</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30056767</ArticleId><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="doi">10.1080/14760584.2018.1506333</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mach O, Tangermann RH, Wassilak SG, et al. Outbreaks of paralytic poliomyelitis during 1996-2012: the changing epidemiology of a disease in the final stages of eradication. J Infect Dis. 2014;210(Suppl 1):S275&#x2013;S282.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316846</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM.. Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers. Vaccine. 2017;35(31):3823&#x2013;3833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5488262</ArticleId><ArticleId IdType="pubmed">28606811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Kew OM, Cochi SL, et al. Poliovirus vaccine &#x2013; live In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia: Saunders Elsevier; 2013. p. 598&#x2013;645.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines. 2012;11(4):449&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">22551030</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Expert Rev Vaccines. 2014;13(2):221&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">24308581</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Rev Vaccines. 2017;16(6):577&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437234</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(Suppl1):S380&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, J-H K, et al Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;23(4):680&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O, Morris-Glasgow V, Landaverde M, et al Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science (80-). 2002;296(5566):356&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassilak SGF, Pate MA, Wannemuehler K, et al Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011;203(7):898&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068031</ArticleId><ArticleId IdType="pubmed">21402542</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Assembly Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). Geneva: World Health Organization; 2008.</Citation></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014;210(Suppl 1):S398&#x2013;S411.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014;210(Suppl 1):S412&#x2013;S423.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316863</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative 
Global eradication of wild poliovirus type 2 declared. 2015.  [cited 2015 Nov 30]. Available from: http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. Morbidity Mortality Weekly Report. 2016;65(35):934&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis. 2016;16:237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896540</ArticleId><ArticleId IdType="pubmed">22804479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis. 1984;6(Suppl 2):S457&#x2013;S460.</Citation><ArticleIdList><ArticleId IdType="pubmed">6330841</ArticleId></ArticleIdList></Reference><Reference><Citation>Oostvogel P, van Wijngaarden J, Hg VDA, et al Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-3. The Lancet. 1994;344(8923):665&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">7915354</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander LN, Seward JF, Santibanez TA, et al Vaccine policy changes and epidemiology of poliomyelitis in the United States. J Am Med Assoc. 2004;292(14):1696&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pubmed">15479934</ArticleId></ArticleIdList></Reference><Reference><Citation>Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg. 1962;76:173&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">14469861</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis E, Kopel E, Singer S, et al Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 2013;18(38):pii=20586.</Citation><ArticleIdList><ArticleId IdType="pubmed">24084337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800&#x2013;1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(Suppl1):S475&#x2013;S484.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316870</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;s Lago P, Bravo JR, Andrus JK, et al Lesson from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ. 1994;72(2):221&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486525</ArticleId><ArticleId IdType="pubmed">8205641</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;s Lago P, Gary HE Jr., P&#xe9;rez LS, et al Poliovirus detection in wastewater and stools following an immunization campaign in Havana. Cuba. Int J Epidemiol. 2003;32:772&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559748</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G, Klapsa D, Wilton T, et al. Years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative. PLoS Pathog. 2015;11(8):e1005114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552295</ArticleId><ArticleId IdType="pubmed">26313548</ArticleId></ArticleIdList></Reference><Reference><Citation>MacCallum FO.Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Medical Research Council Special Report Series, 310, 72&#x2013;85 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">4324778</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15:379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574619</ArticleId><ArticleId IdType="pubmed">26382043</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Bolivar-Wagers S, Srinivas N, et al. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5529169</ArticleId><ArticleId IdType="pubmed">25600519</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G, Liao Y, Takane M, et al Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder: an analysis of the World Health Organization Registry. Front Immunol. 2017;8:1103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5622164</ArticleId><ArticleId IdType="pubmed">28993765</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M, Soleyman-Jahi S, Abolhassani H, et al New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36(13):1711&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pubmed">29478755</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman LM, Manor Y, Sofer D, et al Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS One. 2006;1:e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1762338</ArticleId><ArticleId IdType="pubmed">17183700</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M, Blomqvist S, Al-Hello H, et al Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surveill. 2010;15(19):pii/19566.</Citation><ArticleIdList><ArticleId IdType="pubmed">20483108</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, et al. Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems. Food Environ Virol. 2017;9(4):361&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879701</ArticleId><ArticleId IdType="pubmed">28687986</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential OPV cessation risk management strategy. Epidemiol Infect. 2017;145(2):217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5197684</ArticleId><ArticleId IdType="pubmed">27760579</ArticleId></ArticleIdList></Reference><Reference><Citation>Duizer E, Ruijs WL, van der Weijden CP, et al. Response to a wild poliovirus type 2 (WPV2)-shedding event following accidental exposure to WPV2, the Netherlands, April 2017. Euro Surveill. 2017;22(21):pii=30542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479986</ArticleId><ArticleId IdType="pubmed">28597830</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. 2015;15:389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization 
Global polio eradication initiative: polio eradication and endgame strategic plan (2013-2018). Geneva; 2013.  Available from: http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management. J Vaccines Vaccination. 2016;7(5):339.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">23521018</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, et al. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. Med Decis Making Policy Pract. 2017;2:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6124926</ArticleId><ArticleId IdType="pubmed">30288417</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, et al. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccination. 2016;7(5):340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5497833</ArticleId><ArticleId IdType="pubmed">28690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis. 2018;18:165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5892013</ArticleId><ArticleId IdType="pubmed">29631539</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J, Diop OM, Iber J, et al Update on vaccine-derived polioviruses - worldwide, January 2016-June 2017. MMWR Morb Mortal Wkly Rep. 2017;66(43):1185&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5689216</ArticleId><ArticleId IdType="pubmed">29095803</ArticleId></ArticleIdList></Reference><Reference><Citation>Etsano A, Damisa E, Shuaib F, et al Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission - Nigeria, 2016. Morbidity Mortality Weekly Report. 2016;65(30):770&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">27490081</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. Risk Anal. 2018. Jan 3. doi: 10.1111/risa.12962. [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12962</ArticleId><ArticleId IdType="pmc">PMC7879700</ArticleId><ArticleId IdType="pubmed">29314143</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Meeting of the strategic advisory group of experts on immunization, April 2012 - conclusions and recommendations. Weekly Epidemiological Record. 2012;87(21):204&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">24340402</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Meeting of the strategic advisory group of experts on immunization, April 2016 - conclusions and recommendations. Weekly Epidemiological Record. 2016;91(21):266&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">27236869</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative 
Post-certification strategic plan: a risk mitigation strategy for a polio-free world. 2017.  Available from: http://polioeradication.org/wp-content/uploads/2017/11/polio-post-certification-strategic-plan-draft-17112017.pdf</Citation></Reference><Reference><Citation>World Health Organization 
Polio this week as of 17 April 2018. 2018.  Available from: http://polioeradication.org/polio-today/polio-now/this-week/</Citation></Reference><Reference><Citation>World Health Organization 
Circulating vaccine-derived poliovirus. 2018.  Available from: http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative 
Responding to a poliovirus event and outbreak &#x2013; part 2: protocol for poliovirus type 2. 2017.  Available from: http://polioeradication.org/wp-content/uploads/2017/05/POL-SOPs-Part-2-260517-.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative 
Responding to a poliovirus event and outbreak &#x2013; part 2: protocol for poliovirus type 2. 2016.  Available from: http://www.polioeradication.org/Portals/0/Document/Resources/PolioEradicators/1a.PolioOutbreakGuideline201604part2.pdf</Citation></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis. 2006;26(6):1541&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184396</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis. 2017;216(Suppl 1):S168&#x2013;S175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853947</ArticleId><ArticleId IdType="pubmed">28838198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis. 2015;15:390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4582727</ArticleId><ArticleId IdType="pubmed">26404780</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiology. 2016;11(12):1549&#x2013;1561.</Citation><ArticleIdList><ArticleId IdType="pubmed">27831742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdle WR, Hgam VDA, de Gourville EM, et al Containment of polioviruses after eradication: characterizing risk to improve management. Risk Anal. 2006;26(6):1449&#x2013;1469.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184392</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, Thompson KM. Poliovirus containment risks and their management. Future Virol. 2018. doi: 10.2217/fvl-2018-0079. In press.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2018-0079</ArticleId><ArticleId IdType="pmc">PMC7885305</ArticleId><ArticleId IdType="pubmed">33598044</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Meeting of the strategic advisory group of experts on immunization, April 2017 - conclusions and recommendations. Weekly Epidemiological Record. 2017;92(22):301&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliovirus AM. Studies during the endgame of the polio eradication program. Jpn J Infect Dis. 2017;70(1):1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27795480</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Assembly Global eradication of poliomyelitis by the year 2000 (resolution 41.28). Geneva: World Health Organization; 1988.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al Economic analysis of the global polio eradication initiative. Vaccine. 2011;29(2):334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">21029809</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>